At the news
? NEUTRALIMPACT 2/10 144 filed Nov 10, 2026 at 14:25 ET
Director Jason Aryeh filed a Form 144 notice to sell 3,000 shares of Ligand Pharmaceuticals Class B common stock, with an estimated aggregate market value of approximately $960,084. The shares were acquired in 2019 via secondary market purchases. This is a relatively small sale relative to the company's $6.1B market cap and the insider's apparent holdings, and the filing signals intent to sell rather than a completed transaction.
- Director Jason Aryeh filed Form 144 to sell 3,000 shares of Class B common stock
- Estimated aggregate market value of the proposed sale is $960,084.19
- Shares were acquired between May 14, 2019 and July 30, 2019 via secondary market purchases
- The proposed sale date is November 10, 2026 on Nasdaq
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access